JP2018524274A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018524274A5 JP2018524274A5 JP2017559093A JP2017559093A JP2018524274A5 JP 2018524274 A5 JP2018524274 A5 JP 2018524274A5 JP 2017559093 A JP2017559093 A JP 2017559093A JP 2017559093 A JP2017559093 A JP 2017559093A JP 2018524274 A5 JP2018524274 A5 JP 2018524274A5
- Authority
- JP
- Japan
- Prior art keywords
- oxo
- composition
- dgla
- epa
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 60
- 239000003814 drug Substances 0.000 claims description 35
- 229940079593 drug Drugs 0.000 claims description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 25
- 206010016654 Fibrosis Diseases 0.000 claims description 21
- 230000004761 fibrosis Effects 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 12
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- 239000003443 antiviral agent Substances 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- JEGJFECBWADGJX-RHDCIPCHSA-N (8Z,11Z,13E)-15-oxoicosa-8,11,13-trienoic acid Chemical compound O=C(/C=C/C=C\C\C=C/CCCCCCC(=O)O)CCCCC JEGJFECBWADGJX-RHDCIPCHSA-N 0.000 claims description 6
- 241000711549 Hepacivirus C Species 0.000 claims description 6
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 5
- 241000700721 Hepatitis B virus Species 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims description 4
- ZMWDTYRCKREXOK-XWJJKCKWSA-N (5Z,8Z,11Z,13E,17Z)-15-oxoicosa-5,8,11,13,17-pentaenoic acid Chemical compound O=C(/C=C/C=C\C\C=C/C\C=C/CCCC(=O)O)C\C=C/CC ZMWDTYRCKREXOK-XWJJKCKWSA-N 0.000 claims description 3
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 claims description 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 102000011690 Adiponectin Human genes 0.000 claims description 2
- 108010076365 Adiponectin Proteins 0.000 claims description 2
- 102000008873 Angiotensin II receptor Human genes 0.000 claims description 2
- 108050000824 Angiotensin II receptor Proteins 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 2
- 208000011594 Autoinflammatory disease Diseases 0.000 claims description 2
- 239000005485 Azilsartan Substances 0.000 claims description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 claims description 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 claims description 2
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims description 2
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims description 2
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims description 2
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims description 2
- 229940126692 CXCR3 antagonist Drugs 0.000 claims description 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 108010072051 Glatiramer Acetate Proteins 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims description 2
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 2
- 108700011259 MicroRNAs Proteins 0.000 claims description 2
- 239000005480 Olmesartan Substances 0.000 claims description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 102000009266 Y-Box-Binding Protein 1 Human genes 0.000 claims description 2
- 108010048626 Y-Box-Binding Protein 1 Proteins 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 229940121359 adenosine receptor antagonist Drugs 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 claims description 2
- 125000005907 alkyl ester group Chemical group 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 230000003367 anti-collagen effect Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 229960002731 azilsartan Drugs 0.000 claims description 2
- KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 claims description 2
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 claims description 2
- 208000013507 chronic prostatitis Diseases 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 229940038717 copaxone Drugs 0.000 claims description 2
- 239000003431 cross linking reagent Substances 0.000 claims description 2
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 claims description 2
- 230000008021 deposition Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 229960004563 eprosartan Drugs 0.000 claims description 2
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims description 2
- 125000004494 ethyl ester group Chemical group 0.000 claims description 2
- 210000004392 genitalia Anatomy 0.000 claims description 2
- 210000002216 heart Anatomy 0.000 claims description 2
- 239000000411 inducer Substances 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- 229960002198 irbesartan Drugs 0.000 claims description 2
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims description 2
- 210000001503 joint Anatomy 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 229960004773 losartan Drugs 0.000 claims description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 210000001370 mediastinum Anatomy 0.000 claims description 2
- 229960005108 mepolizumab Drugs 0.000 claims description 2
- 239000002679 microRNA Substances 0.000 claims description 2
- 229950007699 mogamulizumab Drugs 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 206010028537 myelofibrosis Diseases 0.000 claims description 2
- 210000000651 myofibroblast Anatomy 0.000 claims description 2
- 230000001722 neurochemical effect Effects 0.000 claims description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 229960005117 olmesartan Drugs 0.000 claims description 2
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 239000000902 placebo Substances 0.000 claims description 2
- 229940068196 placebo Drugs 0.000 claims description 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 2
- 201000007094 prostatitis Diseases 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 claims description 2
- 239000003087 receptor blocking agent Substances 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 230000008085 renal dysfunction Effects 0.000 claims description 2
- 201000002793 renal fibrosis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 229960005187 telmisartan Drugs 0.000 claims description 2
- 229960004556 tenofovir Drugs 0.000 claims description 2
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims description 2
- 125000005457 triglyceride group Chemical group 0.000 claims description 2
- 229960004699 valsartan Drugs 0.000 claims description 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims description 2
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 206010050207 Skin fibrosis Diseases 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000000574 retroperitoneal space Anatomy 0.000 description 1
- 229950009513 simtuzumab Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562160863P | 2015-05-13 | 2015-05-13 | |
| US62/160,863 | 2015-05-13 | ||
| PCT/IB2016/000732 WO2016181221A1 (en) | 2015-05-13 | 2016-05-12 | Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021020446A Division JP7229285B2 (ja) | 2015-05-13 | 2021-02-12 | １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018524274A JP2018524274A (ja) | 2018-08-30 |
| JP2018524274A5 true JP2018524274A5 (https=) | 2019-09-05 |
Family
ID=56131573
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017559093A Pending JP2018524274A (ja) | 2015-05-13 | 2016-05-12 | １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法 |
| JP2021020446A Active JP7229285B2 (ja) | 2015-05-13 | 2021-02-12 | １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法 |
| JP2023020423A Withdrawn JP2023065454A (ja) | 2015-05-13 | 2023-02-14 | １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法 |
| JP2025002652A Pending JP2025061087A (ja) | 2015-05-13 | 2025-01-08 | １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021020446A Active JP7229285B2 (ja) | 2015-05-13 | 2021-02-12 | １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法 |
| JP2023020423A Withdrawn JP2023065454A (ja) | 2015-05-13 | 2023-02-14 | １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法 |
| JP2025002652A Pending JP2025061087A (ja) | 2015-05-13 | 2025-01-08 | １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US10047033B2 (https=) |
| EP (1) | EP3294282A1 (https=) |
| JP (4) | JP2018524274A (https=) |
| CN (3) | CN113896628A (https=) |
| HK (1) | HK1250345A1 (https=) |
| MA (1) | MA47141A (https=) |
| WO (1) | WO2016181221A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9682055B2 (en) | 2014-06-04 | 2017-06-20 | Dignity Sciences Limted | Pharmaceutical compositions comprising DGLA and use of same |
| MA47141A (fr) | 2015-05-13 | 2019-11-06 | Ds Biopharma Ltd | Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation |
| CA3129008A1 (en) * | 2015-12-18 | 2017-06-22 | Afimmune Limited | Compositions comprising 15-hepe and methods of using the same |
| CN113164377A (zh) * | 2018-10-18 | 2021-07-23 | Ds生物制药有限公司 | 用于治疗炎性、纤维化和增生性病状的dgla和/或15-hetre |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE47777B1 (en) | 1978-01-23 | 1984-06-13 | Efamol Ltd | Pharmaceutical and dietary composition comprising gamma-linolenic acids |
| US5352700A (en) | 1988-01-14 | 1994-10-04 | Anders Frithz | Use of essential fatty acids for the preparation of a drug for the treatment of infantile seborrheic eczema |
| CA1334002C (en) | 1988-09-28 | 1995-01-17 | Barry D. Sears | Essential fatty acid compositions and methods for the modulation of prostaglandin levels in mammals |
| GB9111900D0 (en) | 1991-06-03 | 1991-07-24 | Efamol Holdings | Fatty acid compositions |
| JPH05186342A (ja) * | 1992-01-10 | 1993-07-27 | Fujirebio Inc | 免疫調節作用を併せもつ抗炎症剤 |
| DE4238869C2 (de) | 1992-11-18 | 1994-09-08 | Wogepharm Gmbh | Mittel zur Behandlung des atopischen Ekzems und anderer entzündlicher Hautkrankheiten |
| GB9301446D0 (en) | 1993-01-26 | 1993-03-17 | Scotia Holdings Plc | Internal radiation damage |
| AU683027B2 (en) | 1993-01-27 | 1997-10-30 | Scotia Holdings Plc | Triglycerides |
| JPH09505562A (ja) | 1993-10-01 | 1997-06-03 | アール．ピー．シェーラー コーポレイション | 香料を小分けして提供する方法および組成物 |
| GB9715444D0 (en) | 1997-07-22 | 1997-09-24 | Scotia Holdings Plc | Therapeutic and dietary compositions |
| JP2000191525A (ja) | 1998-12-25 | 2000-07-11 | Nof Corp | 皮膚外用剤組成物 |
| EP1762557B1 (en) | 2000-02-16 | 2011-04-06 | The Brigham And Women's Hospital, Inc. | Aspirin-triggered lipid mediators |
| JP2002047176A (ja) | 2000-08-04 | 2002-02-12 | Idemitsu Technofine Co Ltd | ＩｇＥ産生抑制剤 |
| US20020188024A1 (en) | 2000-08-23 | 2002-12-12 | Chilton Floyd H. | Fatty acid-containing emulsion with increased bioavailability |
| US20040043013A1 (en) | 2000-12-28 | 2004-03-04 | Mccleary Edward Larry | Metabolic uncoupling therapy |
| DE10121252A1 (de) | 2001-04-30 | 2002-11-07 | Christos C Zouboulis | Behandlung der Akne |
| ATE291910T1 (de) | 2001-05-30 | 2005-04-15 | Laxdale Ltd | Verwendung von coenzym q (ubiquinone) und eikosapentaensäure (epa) für die behandlung von non-hodgkin's lymphoma und psychiatrischen oder neurologischen erkrankungen |
| JP2003155233A (ja) | 2001-11-16 | 2003-05-27 | Idemitsu Technofine Co Ltd | 塗布剤 |
| KR20050083960A (ko) | 2002-11-22 | 2005-08-26 | 닛폰 스이산 가부시키가이샤 | 고도 불포화 지방산, 그 염, 또는 그 에스테르를 함유하는외용 조성물 |
| JP2005179211A (ja) | 2003-12-17 | 2005-07-07 | Idemitsu Kosan Co Ltd | 皮膚外用剤組成物 |
| EP1711173A2 (en) | 2003-12-31 | 2006-10-18 | Igennus Limited | Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof |
| AU2005262392A1 (en) | 2004-07-01 | 2006-01-19 | Johnson & Johnson Vision Care, Inc. | Compositions and methods for treating eye disorders and conditions |
| US7666447B2 (en) | 2004-10-08 | 2010-02-23 | Pharmanutrients | Compositions including Krill extracts and conjugated linoleic acid and methods of using same |
| US7893106B2 (en) | 2004-11-19 | 2011-02-22 | Martek Biosciences, Corporation | Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same |
| EP3581178B1 (en) | 2005-02-14 | 2023-08-30 | Suntory Holdings Limited | Composition containing dihomo-(gamma)-linolenic acid (dgla) as active ingredient |
| JP5101894B2 (ja) | 2007-01-15 | 2012-12-19 | サントリーホールディングス株式会社 | 高度不飽和脂肪酸及びこれを含有する脂質の製造方法 |
| PE20100156A1 (es) | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
| US20110105510A1 (en) | 2008-06-17 | 2011-05-05 | Hiroshi Ishikawa | Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis |
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| CA2690488C (en) | 2010-01-19 | 2013-06-11 | Accucaps Industries Limited | Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof |
| US20120264824A1 (en) | 2011-04-15 | 2012-10-18 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| MX360979B (es) | 2011-09-16 | 2018-11-22 | Galectin Therapeutics Inc | Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y de la enfermedad del higado graso no alcohólico. |
| US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| RS57777B1 (sr) | 2012-01-06 | 2018-12-31 | Omthera Pharmaceuticals Inc | Dpa-obogaćene kompozicije omega-3 polinezasićenih masnih kiselina u obliku slobodne kiseline |
| US20130267598A1 (en) * | 2012-02-23 | 2013-10-10 | Dignity Sciences Limited | Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same |
| WO2013150386A2 (en) | 2012-04-04 | 2013-10-10 | Pronova Biopharma Norge As | Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof |
| MX372724B (es) * | 2012-12-24 | 2020-06-19 | Qualitas Health Inc | Formulaciones de acido eicosapentaenoico (epa). |
| GB201301626D0 (en) * | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| US9889108B2 (en) * | 2013-03-15 | 2018-02-13 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| TWI742541B (zh) | 2013-03-15 | 2021-10-11 | 英商邊緣生物科技有限公司 | 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 |
| US9682055B2 (en) | 2014-06-04 | 2017-06-20 | Dignity Sciences Limted | Pharmaceutical compositions comprising DGLA and use of same |
| MA41120A (fr) | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
| MA47141A (fr) | 2015-05-13 | 2019-11-06 | Ds Biopharma Ltd | Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation |
| CA3129008A1 (en) | 2015-12-18 | 2017-06-22 | Afimmune Limited | Compositions comprising 15-hepe and methods of using the same |
| CA3027867A1 (en) | 2016-01-07 | 2017-07-13 | Ds Biopharma Limited | Pharmaceutical compositions comprising dgla and use of same |
-
2016
- 2016-05-12 MA MA047141A patent/MA47141A/fr unknown
- 2016-05-12 WO PCT/IB2016/000732 patent/WO2016181221A1/en not_active Ceased
- 2016-05-12 CN CN202111198132.6A patent/CN113896628A/zh active Pending
- 2016-05-12 HK HK18109827.0A patent/HK1250345A1/zh unknown
- 2016-05-12 US US15/153,476 patent/US10047033B2/en active Active
- 2016-05-12 CN CN202311320835.0A patent/CN117402059A/zh active Pending
- 2016-05-12 JP JP2017559093A patent/JP2018524274A/ja active Pending
- 2016-05-12 EP EP16729367.9A patent/EP3294282A1/en active Pending
- 2016-05-12 CN CN201680040919.0A patent/CN107847477A/zh active Pending
-
2018
- 2018-03-14 US US15/921,211 patent/US10570083B2/en active Active
-
2020
- 2020-01-13 US US16/741,015 patent/US20210230094A1/en not_active Abandoned
-
2021
- 2021-02-12 JP JP2021020446A patent/JP7229285B2/ja active Active
- 2021-11-16 US US17/527,440 patent/US12017986B2/en active Active
-
2023
- 2023-02-14 JP JP2023020423A patent/JP2023065454A/ja not_active Withdrawn
-
2025
- 2025-01-08 JP JP2025002652A patent/JP2025061087A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536380A5 (https=) | ||
| JP2018524274A5 (https=) | ||
| JP7030656B2 (ja) | ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ－γキナーゼ阻害剤とを含有する薬学的組成物 | |
| Strazzabosco et al. | Pathophysiologic implications of innate immunity and autoinflammation in the biliary epithelium | |
| JP7548567B2 (ja) | Ｉｌ－３３を含有するマトリックス結合型小胞（ｍｂｖｓ）およびそれらの使用 | |
| CN118852054A (zh) | 苯并硫杂二氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途 | |
| CN114761018A (zh) | 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 | |
| JP2021506900A (ja) | Ｃ５ａＲ阻害剤としてのジアリール置換５，５−縮合環化合物 | |
| JP2018532720A (ja) | 線維症の治療のためのセニクリビロック併用療法 | |
| JP2022031813A (ja) | １５－ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法 | |
| JP2012021001A5 (https=) | ||
| JP2012505837A5 (https=) | ||
| JP2012505160A (ja) | 炎症を処置する方法 | |
| Luo et al. | Inhibition of macrophage migration inhibitory factor (MIF) as a therapeutic target in bleomycin-induced pulmonary fibrosis rats | |
| JP7229285B2 (ja) | １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法 | |
| JP2017530163A5 (https=) | ||
| WO2014190316A1 (en) | Anti-ccl2 and anti-loxl2 combination therapy for treatment of scleroderma | |
| WO2018051230A1 (en) | Combination of fxr agonists | |
| JP2011503008A5 (https=) | ||
| CN106714842B (zh) | 包含双重PI3K δ-γ激酶抑制剂和皮质类固醇的治疗方法及组合物 | |
| JP2023531930A5 (https=) | ||
| WO2025134073A2 (en) | Methods and compositions for treating diseases or conditions induced by corticosteroids, synovial inflammation, and degenerative joint disease | |
| Veteskova et al. | SDF-1 and its receptor in the ventricles of rat with monocrotaline-induced pulmonary hypertension | |
| Mann et al. | EPIGENETIC REGULATION OF PRO-FIBROGENIC GENES INVOLVED IN HEPATIC STELLATE CELL ACTIVATION AND LIVER FIBROSIS: 1992 | |
| Yang et al. | (5R)-5-Hydroxytriptolide ameliorates lupus nephritis in MRL/lpr mice by 2 preventing infiltration of immune cells 3 |